[go: up one dir, main page]

MA30324B1 - Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. - Google Patents

Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.

Info

Publication number
MA30324B1
MA30324B1 MA31270A MA31270A MA30324B1 MA 30324 B1 MA30324 B1 MA 30324B1 MA 31270 A MA31270 A MA 31270A MA 31270 A MA31270 A MA 31270A MA 30324 B1 MA30324 B1 MA 30324B1
Authority
MA
Morocco
Prior art keywords
benzimidazoles
receptor
activity
medicine
compounds
Prior art date
Application number
MA31270A
Other languages
English (en)
Inventor
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Yann Louchart
Graham Walker
Paul Adrian Wyman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30324B1 publication Critical patent/MA30324B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Benzimidazoles ayant une activité au niveau du récepteur M1 et leurs utilisations en médecine Des composés de formule (I), leurs sels et produits de solvatation sont proposés : dans laquelle Q, R et R6 sont tels que définis dans les revendications. Des utilisations des composés à des fins de thérapie, par exemple dans le traitement de troubles psychotiques et de l'altération cognitive, sont également décrites.
MA31270A 2006-03-22 2008-10-07 Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. MA30324B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0605786.3A GB0605786D0 (en) 2006-03-22 2006-03-22 Compounds

Publications (1)

Publication Number Publication Date
MA30324B1 true MA30324B1 (fr) 2009-04-01

Family

ID=36383995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31270A MA30324B1 (fr) 2006-03-22 2008-10-07 Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.

Country Status (22)

Country Link
US (3) US20100280071A1 (fr)
EP (1) EP2004182B1 (fr)
JP (1) JP5256187B2 (fr)
KR (1) KR20090015027A (fr)
CN (2) CN101448495B (fr)
AR (1) AR059977A1 (fr)
AU (1) AU2007228716A1 (fr)
BR (1) BRPI0708999A2 (fr)
CA (1) CA2646896A1 (fr)
CR (1) CR10314A (fr)
EA (1) EA200870360A1 (fr)
GB (1) GB0605786D0 (fr)
IL (1) IL194206A0 (fr)
MA (1) MA30324B1 (fr)
MX (1) MX2008012160A (fr)
NO (1) NO20084048L (fr)
NZ (1) NZ595738A (fr)
PE (1) PE20080007A1 (fr)
SG (1) SG170752A1 (fr)
TW (1) TW200813004A (fr)
WO (1) WO2007107565A1 (fr)
ZA (1) ZA200807616B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
EP2194982A1 (fr) 2007-09-20 2010-06-16 Glaxo Group Limited Composés présentant une activité au niveau du récepteur m1 et leurs utilisations en médecine
PE20091194A1 (es) * 2007-09-20 2009-09-05 Glaxo Group Ltd Derivados de heterociclicos como moduladores del receptor m1
WO2009124883A1 (fr) * 2008-04-09 2009-10-15 H. Lundbeck A/S Nouveaux 1,3-dihydro-benzoimidazol-2-ones utilisés en tant qu’agonistes m1
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
JP5990980B2 (ja) * 2012-04-02 2016-09-14 大日本印刷株式会社 オランザピンの中間体の製造方法
CA3008272A1 (fr) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methodes de traitement du cancer
WO2017106332A1 (fr) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
EP3393468B1 (fr) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Méthodes pour le traitement d'une maladie immunodéficiente
CN107129439A (zh) * 2016-02-26 2017-09-05 中国科学院大连化学物理研究所 一种化合物、毒蕈碱m受体拮抗剂、组合物及应用
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027500A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CN116554168B (zh) 2016-06-21 2025-09-23 X4制药有限公司 Cxcr4抑制剂及其用途
CN109640988A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021183650A1 (fr) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Méthodes de traitement de la neutropénie
CN113637001A (zh) * 2021-08-09 2021-11-12 安康市农业科学研究院 一种氟哌利多中间体的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4040300A1 (de) * 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
AU701127B2 (en) * 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (fr) * 1995-10-31 1997-05-09 Merck & Co., Inc. Agonistes de la muscarine
JPH10330377A (ja) * 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6423725B1 (en) * 1998-01-19 2002-07-23 Pfizer Inc 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
DE60022226D1 (de) * 1999-12-06 2005-09-29 Euro Celtique Sa Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
WO2004089942A2 (fr) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Derives de benzimidazolidinone utilises en tant qu'agents muscariniques
US7279490B2 (en) * 2002-06-17 2007-10-09 Merck & Co, Inc. Ophthalmic compositions for treating ocular hypertension
AU2003300902A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Piperidine derivatives as CCR5 antagonists
JP5209479B2 (ja) * 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類

Also Published As

Publication number Publication date
CN101448495A (zh) 2009-06-03
PE20080007A1 (es) 2008-03-16
NO20084048L (no) 2008-10-20
WO2007107565A1 (fr) 2007-09-27
US20120316202A1 (en) 2012-12-13
CN103058990A (zh) 2013-04-24
TW200813004A (en) 2008-03-16
AU2007228716A1 (en) 2007-09-27
MX2008012160A (es) 2008-10-03
US20120041028A1 (en) 2012-02-16
GB0605786D0 (en) 2006-05-03
ZA200807616B (en) 2010-07-28
EP2004182A1 (fr) 2008-12-24
JP2009530347A (ja) 2009-08-27
KR20090015027A (ko) 2009-02-11
EP2004182B1 (fr) 2013-05-08
CN101448495B (zh) 2013-05-08
CA2646896A1 (fr) 2007-09-27
US20100280071A1 (en) 2010-11-04
EA200870360A1 (ru) 2009-02-27
JP5256187B2 (ja) 2013-08-07
NZ595738A (en) 2012-11-30
SG170752A1 (en) 2011-05-30
CR10314A (es) 2008-12-01
IL194206A0 (en) 2009-08-03
AR059977A1 (es) 2008-05-14
BRPI0708999A2 (pt) 2011-06-21

Similar Documents

Publication Publication Date Title
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
MA28011A1 (fr) Derives de piperazine et leur utilisation en tant qu'agents therapeutiques
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
ATE444066T1 (de) Liganden für den cannabinoidrezeptoren
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
MA29404B1 (fr) Preparation pharmaceutique
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
CY1110316T1 (el) Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
MA29723B1 (fr) Composes